Table 2.
Clinical and pathological characteristics of sensitive and insensitive patients in the test and training cohort
| Test cohort | p | Training cohort | p | |||
|---|---|---|---|---|---|---|
| Sensitive | Insensitive | Sensitive | Insensitive | |||
| Amount | 32 | 13 | 77 | 30 | ||
| Age (years) mean ± SD, years | 47.53 ± 11.44 | 48.62 ± 9.37 | 0.764 | 48.83 ± 10.56 | 50.07 ± 10.83 | 0.591 |
| Clinical stage(%) | ||||||
| I | 0 (0.0%) | 0 (0.0%) | 0.893 | 2 (2.6%) | 0 (0.0%) | 0.554 |
| II | 19 (59.4%) | 8 (61.5%) | 35 (45.5%) | 16 (53.3%) | ||
| III | 13 (40.6%) | 5 (38.5%) | 40 (51.9%) | 14 (46.7%) | ||
| Histopathological subtype(%) | ||||||
| IDC | 29 (90.6%) | 11 (84.6%) | 0.519 | 72 (93.5%) | 23 (76.7%) | 0.046a |
| IDC + ILC/+IMPC/+Mucinous cancer | 1 (3.1%) | 0 (0.0%) | 3 (3.9%) | 4 (13.3%) | ||
| ILC/IMPC/Mucinous cancer | 2 (6.3%) | 2 (15.4%) | 2 (2.6%) | 3 (10%) | ||
| Molecular subtype(%) | ||||||
| Luminal A | 1 (3.1%) | 6 (46.2%) | 0.002a | 10 (13.0%) | 12 (40.0%) | 0.004a |
| Luminal B | 11 (34.4%) | 2 (15.4%) | 36 (46.8%) | 7 (23.3%) | ||
| Triple negative | 5 (15.6%) | 3 (23.0%) | 8 (10.4%) | 6 (20.0%) | ||
| HER2 overexpression | 15 (46.9%) | 2 (15.4%) | 23 (29.8%) | 5 (16.7%) | ||
| ER status(%) | ||||||
| Positive | 12 (37.5%) | 8 (61.5%) | 0.141 | 46 (59.7%) | 19 (63.3%) | 0.732 |
| Negative | 20 (62.5%) | 5 (38.5%) | 31 (40.3%) | 11 (36.7%) | ||
| PR status(%) | ||||||
| Positive | 10 (31.2%) | 8 (61.5%) | 0.060 | 39 (50.6%) | 16 (53.3%) | 0.803 |
| Negative | 22 (68.8%) | 5 (38.5%) | 38 (49.4%) | 14 (46.7%) | ||
| HER2 status(%) | ||||||
| Positive | 22 (68.8%) | 3 (23.1%) | 0.005a | 30 (39.0%) | 22 (73.3%) | 0.001a |
| Negative | 10 (31.2%) | 10 (76.9%) | 47 (61.0%) | 8 (26.7%) | ||
| Ki67(%) | ||||||
| High | 11 (34.4%) | 9 (69.2%) | 0.033a | 36 (46.8%) | 12 (40.0%) | 0.049a |
| Low | 21 (65.6%) | 4 (30.8%) | 41 (53.2%) | 18 (60.0%) | ||
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2;IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IMPC, invasive micropapillary carcinoma; PR, progesterone receptor.
a
p‹0.05